1-3 of 3
John Byrd, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.

Neil Kay, MD, Susan Geyer, PhD, Timothy Call, MD, Tait Shanafelt, MD, Clive Zent, MD, Diane Jelinek, PhD, Renee Tschumper, Nancy Bone, Gordon Dewald, PhD, Thomas Lin, PhD, Nyla Heerema, PhD, Laura Smith, Michael Grever, MD, John Byrd, MD
Journal: Blood
Blood (2006) 108 (11): 35.
https://doi.org/10.1182/blood.V108.11.35.35
Published: 2006
Journal Articles

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Wendy Stock, MD, Daohai Yu, PhD, Ben Sanford, MS, Gerard Lozanski, Ph.D, Spero Cataland, MD, Ravi Vij, MD, John Byrd, MD, Bayard Powell, MD, Meir Wetzler, MD, Maher Albitar, MD, Dorie Sher, BS, Colin Edwards, MS, Eva Hoke, BS, Clara D. Bloomfield, MD, Richard A. Larson, MD
Journal: Blood
Blood (2005) 106 (11): 145.
https://doi.org/10.1182/blood.V106.11.145.145
Published: 2005
Journal Articles

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Amy Johnson, PhD, Lisa Smith, Jiuxiang Zhu, Nyla Heerema, PhD, Sara Guster, Andrew Mone, MD, PhD, Michael Grever, MD, Ching-Shih Chen, PhD, John Byrd, MD
Journal: Blood
Blood (2004) 104 (11): 3471.
https://doi.org/10.1182/blood.V104.11.3471.3471
Published: 2004